Key Real-World Indicators Predict Muscarinic Response in Psychosis
In a groundbreaking advance for psychiatric therapeutics, the recent FDA approval of xanomeline/trospium combination—marketed as Cobenfy—marks a pivotal moment in ...
In a groundbreaking advance for psychiatric therapeutics, the recent FDA approval of xanomeline/trospium combination—marketed as Cobenfy—marks a pivotal moment in ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine